{
  "report_rows": [
    {
      "kpi": "Q2 2026 non-GAAP operating EPS",
      "prediction": "BEAT",
      "answer": "pred ~$1.92 vs. cons $1.79",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 P&C combined ratio",
      "prediction": "BEAT",
      "answer": "pred ~96.2% vs. cons 97.4%",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 P&C net written-premium growth",
      "prediction": "MISS",
      "answer": "pred ~6% vs. cons 7%",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Management-implied P&C combined ratio outlook",
      "prediction": "BETTER",
      "answer": "guide ~95.6% vs. cons 96.0% (FY2026)",
      "confidence": "LOW"
    },
    {
      "kpi": "Management-implied P&C net written-premium growth outlook",
      "prediction": "LOWER",
      "answer": "guide ~6% vs. cons 7% (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Commercial-lines renewal pricing commentary",
      "prediction": "LOWER",
      "answer": "guide ~3% vs. cons 4% (H2 2026)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 1.8,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 0.5,
  "day5_path": "FADE",
  "day5_rationale": "A catastrophe-aided EPS and combined-ratio beat should initially support the shares, but slower premium growth and commercial pricing of ~3% versus ~4% expected imply modest out-period estimate pressure. With valuation already demanding, the day-1 gain is likely to fade while remaining slightly positive over five days.",
  "day5_confidence": "MEDIUM"
}